Glucose uptake inhibitor sensitizes cancer cells to daunorubicin and overcomes drug resistance in hypoxia

Cancer Chemotherapy and Pharmacology

Volumn 59, Issue 4, 2007, Pages 495-505

  Cao, Xianhua ^a   Fang, Lanyan ^a   Gibbs, Seth ^a   Huang, Ying ^a   Dai, Zunyan ^a   Wen, Ping ^a   Zheng, Xincheng ^a   Sadee, Wolfgang ^a   Sun, Duxin ^a  

^a OHIO STATE UNIVERSITY   (United States)

Author keywords

Combination; Drug resistance; Glucose transporter; Glycolysis inhibitor; Hypoxia

Indexed keywords

DAUNORUBICIN; DEOXYGLUCOSE; FLUORESCEIN ISOTHIOCYANATE; GLUCOSE TRANSPORTER; GLUCOSE TRANSPORTER 1; LIPOCORTIN 5; PHLORETIN;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER; CANCER CELL CULTURE; CANCER RESISTANCE; CANCER TISSUE; CELL SURVIVAL; CONTROLLED STUDY; CYTOTOXICITY; DNA MICROARRAY; DRUG SENSITIZATION; GENE EXPRESSION; GLUCOSE TRANSPORT; HUMAN; HUMAN CELL; HUMAN TISSUE; HYPOXIA; IMMUNOHISTOCHEMISTRY; MONITORING; PRIORITY JOURNAL;

APOPTOSIS; CELL HYPOXIA; CELL LINE, TUMOR; DAUNORUBICIN; DRUG RESISTANCE, NEOPLASM; DRUG SYNERGISM; GLUCOSE; GLUCOSE TRANSPORT PROTEINS, FACILITATIVE; GLUCOSE TRANSPORTER TYPE 1; GLUCOSE TRANSPORTER TYPE 3; HUMANS; NEOPLASMS; PHLORETIN;

EID: 33846270366     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00280-006-0291-9     Document Type: Article

References (37)

1. Warburg O (1956) On the origin of cancer cells. Science 123:309-314
2. Gatenby RA (1995) The potential role of transformation-induced metabolic changes in tumor-host interaction. Cancer Res 55:4151-4156
3. Dang CV, Semenza GL (1999) Oncogenic alterations of metabolism. Trends Biochem Sci 24:68-72
4. Seagroves TN, Ryan HE, Lu H, Wouters BG, Knapp M, Thibault P, Laderoute K, Johnson RS (2001) Transcription factor HIF-1 is a necessary mediator of the pasteur effect in mammalian cells. Mol Cell Biol 21:3436-3444
5. Hockel M, Vaupel P (2001) Tumor hypoxia: definitions and current clinical, biologic, and molecular aspects. J Natl Cancer Inst 93:266-276
6. Hockel M, Schlenger K, Hockel S, Vaupel P (1999) Hypoxic cervical cancers with low apoptotic index are highly aggressive. Cancer Res 59:4525-4528
7. Gambhir SS (2002) Molecular imaging of cancer with positron emission tomography. Nat Rev Cancer 2:683-693
8. Gallagher BM, Ansari A, Atkins H, Casella V, Christman DR, Fowler JS, Ido T, MacGregor RR, Som P, Wan CN, Wolf AP, Kuhl DE, Reivich M (1977) Radiopharmaceuticals XXVII. 18F-labeled 2-deoxy-2-fluoro-d-glucose as a radiopharmaceutical for measuring regional myocardial glucose metabolism in vivo tissue distribution and imaging studies in animals. J Nucl Med 18:990-996
9. Penta JS, Johnson FM, Wachsman JT, Copeland WC (2001) Mitochondrial DNA in human malignancy. Mutat Res 488:119-133
10. Carew JS, Huang P (2002) Mitochondrial defects in cancer. Mol Cancer 1:9
11. Xu RH, Pelicano H, Zhou Y, Carew JS, Feng L, Bhalla KN, Keating MJ, Huang P (2005) Inhibition of glycolysis in cancer cells: a novel strategy to overcome drug resistance associated with mitochondrial respiratory defect and hypoxia. Cancer Res 65:613-621
12. Harris AL (2002) Hypoxia - a key regulatory factor in tumour growth. Nat Rev Cancer 2:38-47
13. Chen C, Pore N, Behrooz A, Ismail-Beigi F, Maity A (2001) Regulation of glut1 mRNA by hypoxia-inducible factor-1. Interaction between H-ras and hypoxia. J Biol Chem 276:9519-9525
14. Zelzer E, Levy Y, Kahana C, Shilo BZ, Rubinstein M, Cohen B (1998) Insulin induces transcription of target genes through the hypoxia-inducible factor HIF-1alpha/ARNT. Embo J 17:5085-5094
15. Palmer LA, Johns RA (1998) Hypoxia upregulates inducible (Type II) nitric oxide synthase in an HIF-1 dependent manner in rat pulmonary microvascular but not aortic smooth muscle cells. Chest 114:33S-34S
16. Palmer LA, Semenza GL, Stoler MH, Johns RA (1998) Hypoxia induces type II NOS gene expression in pulmonary artery endothelial cells via HIF-1. Am J Physiol 274:L212-L219
17. Figueroa YG, Chan AK, Ibrahim R, Tang Y, Burow ME, Alam J, Scandurro AB, Beckman BS (2002) NF-kB plays a key role in hypoxia-inducible factor-1-regulated erythropoietin gene expression. Exp Hematol (New York, NY, United States) 30:1419-1427
18. Ivanov S, Liao SY, Ivanova A, Danilkovitch-Miagkova A, Tarasova N, Weirich G, Merrill MJ, Proescholdt MA, Old-field EH, Lee J, Zavada J, Waheed A, Sly W, Lerman MI, Stanbridge EJ (2001) Expression of hypoxia-inducible cell-surface transmembrane carbonic anhydrases in human cancer. Am J Pathol 158:905-919
19. Yamagata M, Hasuda K, Stamato T, Tannock IF (1998) The contribution of lactic acid to acidification of tumours: studies of variant cells lacking lactate dehydrogenase. Br J Cancer 77:1726-1731
20. Joost HG, Bell GI, Best JD, Birnbaum MJ, Charron MJ, Chen YT, Doege H, James DE, Lodish HF, Moley KH, Moley JF, Mueckler M, Rogers S, Schurmann A, Seino S, Thorens B (2002) Nomenclature of the GLUT/SLC2A family of sugar/polyol transport facilitators. Am J Physiol Endocrinol Metab 282:E974-E976
21. Joost HG, Thorens B (2001) The extended GLUT-family of sugar/polyol transport facilitators: nomenclature, sequence characteristics, and potential function of its novel members (review). Mol Membr Biol 18:247-256
22. Kawamura T, Kusakabe T, Sugino T, Watanabe K, Fukuda T, Nashimoto A, Honma K, Suzuki T (2001) Expression of glucose transporter-1 in human gastric carcinoma: association with tumor aggressiveness, metastasis, and patient survival. Cancer 92:634-641
23. Wilson JE (2003) Isozymes of mammalian hexokinase: structure, subcellular localization and metabolic function. J Exp Biol 206:2049-2057
24. Verhagen JN, Van der Heijden MC, Rijksen G, Der Kinderen PJ, Van Unnik JA, Staal GE (1985) Determination and characterization of hexokinase in thyroid cancer and benign neoplasms. Cancer 55:1519-1524
25. Brown RS, Goodman TM, Zasadny KR, Greenson JK, Wahl RL (2002) Expression of hexokinase II and Glut-1 in untreated human breast cancer. Nucl Med Biol 29:443-453
26. Yasuda S, Arii S, Mori A, Isobe N, Yang W, Oe H, Fujimoto A, Yonenaga Y, Sakashita H, Imamura M (2004) Hexokinase II and VEGF expression in liver tumors: correlation with hypoxia-inducible factor-1alpha and its significance. J Hepatol 40:117-123
27. Haberkorn U, Morr I, Oberdorfer F, Bellemann ME, Blatter J, Altmann A, Kahn B, van Kaick G (1994) Fluorodeoxyglucose uptake in vitro: aspects of method and effects of treatment with gemcitabine. J Nucl Med 35:1842-1850
28. Burt BM, Humm JL, Kooby DA, Squire OD, Mastorides S, Larson SM, Fong Y (2001) Using positron emission tomography with [(18)F]FDG to predict tumor behavior in experimental colorectal cancer. Neoplasia 3:189-195
29. Anderle P, Rakhmanova V, Woodford K, Zerangue N, Sadee W (2003) Messenger RNA expression of transporter and ion channel genes in undifferentiated and differentiated Caco-2 cells compared to human intestines. Pharm Res 20:3-15
30. Huang Y, Anderle P, Bussey KJ, Barbacioru C, Shankavaram U, Dai Z, Reinhold WC, Papp A, Weinstein JN, Sadee W (2004) Membrane transporters and channels: role of the transportome in cancer chemosensitivity and chemoresistance. Cancer Res 64:4294-4301
31. Scherf U, Ross DT, Waltham M, Smith LH, Lee JK, Tanabe L, Kohn KW, Reinhold WC, Myers TG, Andrews DT, Scudiero DA, Eisen MB, Sausville EA, Pommier Y, Botstein D, Brown PO, Weinstein JN (2000) A gene expression database for the molecular pharmacology of cancer. Nat Genet 24:236-244
32. Staunton JE, Slonim DK, Coller HA, Tamayo P, Angelo MJ, Park J, Scherf U, Lee JK, Reinhold WO, Weinstein JN, Mesirov JP, Lander ES, Golub TR (2001) Chemosensitivity prediction by transcriptional profiling. Proc Natl Acad Sci USA 98:10787-10792
33. Eisen MB, Spellman PT, Brown PO, Botstein D (1998) Cluster analysis and display of genome-wide expression patterns. Proc Natl Acad Sci USA 95:14863-14868
34. Unruh A, Ressel A, Mohamed HG, Johnson RS, Nadrowitz R, Richter E, Katschinski DM, Wenger RH (2003) The hypoxia-inducible factor-1 alpha is a negative factor for tumor therapy. Oncogene 22:3213-3220
35. Brown JM, Wilson WR (2004) Exploiting tumour hypoxia in cancer treatment. Nat Rev Cancer 4:437-447
36. Koch S, Mayer F, Honecker F, Schittenhelm M, Bokemeyer C (2003) Efficacy of cytotoxic agents used in the treatment of testicular germ cell tumours under normoxic and hypoxic conditions in vitro. Br J Cancer 89:2133-2139
37. Gottesman MM, Fojo T, Bates SE (2002) Multidrug resistance in cancer: role of ATP-dependent transporters. Nat Rev Cancer 2:48-58